Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:06:46 EST Sat 13 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:CVKD - CADRENAL THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CVKD - Q5.010.83·15.000.211.00105.01,1061,11311.34  11.4359  10.8322.9011  8.1218:47:3811:0015 min RT 2¢

Recent Trades - Last 10 of 1113
Time ETExPriceChangeVolume
18:47:38Q11.400.401
18:04:59Q10.80-0.201
16:10:03Q11.00 1
16:05:12Q11.150.1525
16:04:01Q11.00 1
16:00:02Q11.00 10
16:00:02Q11.00 84
16:00:02Q11.00 21
16:00:02Q11.00 10
16:00:02Q11.00 187

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-12 11:00U:CVKDNews ReleaseCadrenal's Quiet Expansion Play Is Starting to Get Loud
2025-12-12 09:45U:CVKDNews ReleaseCadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
2025-12-11 08:05U:CVKDNews ReleaseCadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
2025-12-01 09:00U:CVKDNews ReleaseCadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
2025-11-19 08:00U:CVKDNews ReleaseCadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award
2025-11-10 09:00U:CVKDNews ReleaseCadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-09-29 16:30U:CVKDNews ReleaseCadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
2025-09-15 08:00U:CVKDNews ReleaseCadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors
2025-08-11 08:00U:CVKDNews ReleaseCadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-05 06:00U:CVKDNews ReleaseCadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
2025-06-12 08:00U:CVKDNews ReleaseCadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
2025-06-04 08:00U:CVKDNews ReleaseCadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
2025-05-15 07:30U:CVKDNews ReleaseCadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
2025-05-08 08:00U:CVKDNews ReleaseCadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
2025-04-03 08:00U:CVKDNews ReleaseCadrenal Therapeutics Participates in Key Medical and Business Development Conferences
2025-03-13 16:05U:CVKDNews ReleaseCadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
2025-03-04 08:00U:CVKDNews ReleaseCadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3(TM) LVAD
2025-02-06 09:00U:CVKDNews ReleaseCadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
2025-02-05 09:00U:CVKDNews ReleaseCadrenal Therapeutics to Present at BIO CEO & Investor Conference
2025-01-09 08:44U:CVKDNews ReleaseCadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025